Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.
Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 16 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.
Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anthrax - Overview
Anthrax - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anthrax - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anthrax - Companies Involved in Therapeutics Development
Aphios Corp
Biologics Resources LLC
BlueWillow Biologics Inc
China Biologic Products Holdings Inc
Crestone Inc
Dynavax Technologies Corp
Emergent BioSolutions Inc
GC Pharma
Greffex Inc
Hawaii Biotech Inc
iBio Inc
Innovative Biologics Inc
Integrated BioTherapeutics Inc
iNtRON Biotechnology Inc
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Paratek Pharmaceuticals Inc
Protein Potential LLC
ProThera Biologics Inc
Soligenix Inc
Vast Therapeutics Inc
Venomyx Inc
VLP Biotech Inc
Anthrax - Drug Profiles
(anthrax + plague) (multivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
anthrax (virus like particles, bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
anthrax + plague vaccine - Drug Profile
Product Description
Mechanism Of Action
anthrax [strain Alls/Gifford] vaccine - Drug Profile
Product Description
Mechanism Of Action
anthrax vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
anthrax vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antibody for Anthrax - Drug Profile
Product Description
Mechanism Of Action
Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile
Product Description
Mechanism Of Action
AV-7909 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BAL-200 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BDM-I - Drug Profile
Product Description
Mechanism Of Action
BIOC-51 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BW-1010 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CRS-0540 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DV-230F - Drug Profile
Product Description
Mechanism Of Action
GC-1109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GREANX - Drug Profile
Product Description
Mechanism Of Action
History of Events
Marinus - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody for Anthrax - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody for Anthrax - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
Product Description
Mechanism Of Action
History of Events
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
Protein to Inhibit Furin for Anthrax and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Proteins for Anthrax and Methicillin Resistant Staphylococcus Aureus (MRSA) Infections - Drug Profile
Product Description
Mechanism Of Action
RiVax + SGX-204 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rPA-01 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit Anthrax Toxin and Alpha Hemolysin for Anthrax and Staphylococcal aureus Pneumonia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Lethal Factor for Anthrax - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Bacterial Infections and Bone Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Teixobactin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Anthrax - Dormant Projects
Anthrax - Discontinued Products
Anthrax - Product Development Milestones
Featured News & Press Releases
Oct 26, 2021: BlueWillow Biologics to present during BARDA Industry Day 2021
Sep 27, 2021: Paratek Pharmaceuticals announces additional funding under the BARDA contract to advance the development of NUZYRA (omadacycline) for post-exposure prophylaxis (PEP) and treatment of pulmonary anthrax
Aug 24, 2021: BlueWillow Biologics announces positive interim results from phase 1 trial of intranasal anthrax vaccine
Jun 29, 2021: Paratek Pharmaceuticals announces first BARDA project Bioshield procurement of NUZYRA (omadacycline) valued at ~$38 million
Jul 13, 2020: Emergent BioSolutions received a contract modification from the Office of the Assistant Secretary
Mar 10, 2020: Paratek Pharmaceuticals announces the submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)
Dec 18, 2019: Paratek awarded BARDA project BioShield contract for NUZYRA
Oct 23, 2019: BlueWillow receives FDA clearance to begin phase 1 study of its intranasal Anthrax Vaccine
May 29, 2019: BlueWillow Biologics announces issuance of intranasal Anthrax Vaccine patent
May 15, 2019: Emergent BioSolutions prepares for initial shipments of AV7909 anthrax vaccine candidate into the strategic national stockpile
Mar 20, 2019: Emergent BioSolutions launches Phase III trial of anthrax vaccine
Jan 09, 2019: Vast Therapeutics Announces Results Showing Ability to Eradicate Anthrax
Dec 28, 2018: Emergent BioSolutions announces submission to FDA of application covering emergency use authorization for NuThrax
Jun 19, 2017: NanoBio And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine
Jun 22, 2016: U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of NuThrax Vaccines
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anthrax, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Anthrax - Pipeline by Aphios Corp, 2022
Anthrax - Pipeline by Biologics Resources LLC, 2022
Anthrax - Pipeline by BlueWillow Biologics Inc, 2022
Anthrax - Pipeline by China Biologic Products Holdings Inc, 2022
Anthrax - Pipeline by Crestone Inc, 2022
Anthrax - Pipeline by Dynavax Technologies Corp, 2022
Anthrax - Pipeline by Emergent BioSolutions Inc, 2022
Anthrax - Pipeline by GC Pharma, 2022
Anthrax - Pipeline by Greffex Inc, 2022
Anthrax - Pipeline by Hawaii Biotech Inc, 2022
Anthrax - Pipeline by iBio Inc, 2022
Anthrax - Pipeline by Innovative Biologics Inc, 2022
Anthrax - Pipeline by Integrated BioTherapeutics Inc, 2022
Anthrax - Pipeline by iNtRON Biotechnology Inc, 2022
Anthrax - Pipeline by NovoBiotic Pharmaceuticals LLC, 2022
Anthrax - Pipeline by Opal Biosciences Ltd, 2022
Anthrax - Pipeline by Paratek Pharmaceuticals Inc, 2022
Anthrax - Pipeline by Protein Potential LLC, 2022
Anthrax - Pipeline by ProThera Biologics Inc, 2022
Anthrax - Pipeline by Soligenix Inc, 2022
Anthrax - Pipeline by Vast Therapeutics Inc, 2022
Anthrax - Pipeline by Venomyx Inc, 2022
Anthrax - Pipeline by VLP Biotech Inc, 2022
Anthrax - Dormant Projects, 2022
Anthrax - Dormant Projects, 2022 (Contd..1)
Anthrax - Dormant Projects, 2022 (Contd..2)
Anthrax - Dormant Projects, 2022 (Contd..3)
Anthrax - Discontinued Products, 2022
List of Figures
Number of Products under Development for Anthrax, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
